

Impact of Gplife Advance Diabetic support tablet in Diabetes

*Dr. Shridhar J Pandya



Gplife Healthcare Pvt Ltd, India

Abstract

Till date, Diabetic population is going to increase day by day, means something is missing with line of treatment. Diabetes mellitus (DM) is rising in India with more than 62 million diabetic individuals. India (31.7 million) topped world with highest number of people with DM followed by US. Prevalence of DM is predicted to double globally from 171 in 2000 to 366 million in 2030. Gplife Advanced Diabetic Support Tablet was suggestively effective in significantly effective in dropping levels of fasting plasma glucose (FPG) & post meal plasma glucose (PMG). It dropping levels of % HbA1C from baseline to day 60 i.e. end of study. It also significantly effective in increasing levels of C- peptide levels from baseline to day 60 i.e. end of study. C- Peptide is co-secreted with insulin from pancreas and could be used as a tool in diagnosis of DM. When compared to C peptide levels in overall patients there was improvement in c- peptide levels after treatment of Gplife Advanced Diabetic Support Tablet to DM patients. It increases in the HOMA-B score and there was significant decrease in the HOMA-IR score in DM patients. It was concluded that Gplife Advanced Diabetic Support Tablet” used as an adjuvant to OHA and insulin and helps in reducing fasting and post meal blood glucose level along with HbA1c. This can reduce the probable side effects of external insulin and OHA to subjects by providing result oriented and safer alternatives in management of DM



Biography:

Dr. Shridhar J Pandya (Doctor of Philosophy - Pharmaceutical Technology) Managing Director- Gplife Healthcare Pvt Ltd. He got his PhD from JNU & M Pharm from Pune University with Pharmaceutics as a specialization. He has 14 years experience in Pharmaceutical and Nutraceutical research field. He was Professor, Guide of Master's and PhD scholar students. He published more than 25 national and international papers in reputed journals. He invented more than 50 Nutraceutical and dietary supplement formula of various diseases and many

researches are going on. He developed formula with Nutropepathy as an alternative option of people with diabetes & for dosage; He designed Pharmaceutical technology to develop Nutraceuticals and Supplements for miraculous output with target delivery system. He is familiar with design expert, SAS software for Optimization. His developed formula approved with Stability, Microbiological & Heavy metal test. He was chair person & Speaker of various international conferences of Diabetes and received best scientist award for his research was published in reputed journals in London, USA, Thailand, China and Singapore. He received young scientist award with best brand invention sponsored by ABP news. He delivered his research at international level in various Pharmaceutical and Nutraceutical conferences. He is author of number of pharmaceutical research, inventor of Patent & international books. His research articles are going to selected as a reference in US Patent also. He is founder and researcher formula of various diseases like Diabetes, Obesity, Cholesterol, Triglycerides, Colon disease, Kidney, Liver disease, Respiratory, Allergy, Blood disorder, Cancer, Skin disease, Autoimmune disorder and B12 problem.

[3rd International conference on Diabetes, Hypertension and Metabolic Syndrome](#); Webinar- July 02-03, 2020.

Abstract Citation:

Shridhar J Pandya, Impact of Gplife Advance Diabetic support tablet in Diabetes, Diabetes Meet 2020 3rd International conference on Diabetes, Hypertension and Metabolic Syndrome; Webinar -July 02-03, 2020

(<https://diabetesmeet.conferenceseries.com/abstract/2020/impact-of-gplife-advance-diabetic-support-tablet-in-diabetes>)